# Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT

> **NCT07720232** · PHASE4 · RECRUITING · sponsor: **Jianyin Zhou** · enrollment: 180 (estimated)

## Conditions studied

- Hypertriglyceridemic Acute Pancreatitis
- Acute Pancreatitis, Hypertriglyceridemia-induced
- Hyperlipidemia

## Interventions

- **DRUG:** Live Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE)
- **DRUG:** Standard Care (in control arm)

## Key facts

- **NCT ID:** NCT07720232
- **Lead sponsor:** Jianyin Zhou
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-18
- **Primary completion:** 2028-01-18
- **Final completion:** 2029-02-18
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720232, "Bacillus Subtilis and Enterococcus Faecium Probiotic Plus Lipid-Lowering Therapy for Hypertriglyceridemic Acute Pancreatitis: A Prospective RCT". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*